hMG + Cetrorelix acetate + Coriogonadotropin alfa + Progesterone gel
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infertility
Conditions
Infertility
Trial Timeline
Feb 5, 2026 → Jun 30, 2029
NCT ID
NCT07340827About hMG + Cetrorelix acetate + Coriogonadotropin alfa + Progesterone gel
hMG + Cetrorelix acetate + Coriogonadotropin alfa + Progesterone gel is a phase 3 stage product being developed by Merck for Infertility. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07340827. Target conditions include Infertility.
What happened to similar drugs?
11 of 20 similar drugs in Infertility were approved
Approved (11) Terminated (4) Active (9)
🔄GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07340827 | Phase 3 | Recruiting |
Competing Products
20 competing products in Infertility